This HTML5 document contains 189 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
n10http://dx.doi.org/10.1200/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q33380148
rdf:type
wikibase:Item
schema:description
2008年論文 tieteellinen artikkeli articolo scientifico article científic مقالة علمية naučni članak 2008年论文 научная статья videnskabelig artikel (udgivet 2008) мақолаи илмӣ 2008年论文 наукова стаття, опублікована в червні 2008 artigo científico (publicado na 2008) article scientifique (publié 2008) 2008年論文 2008年論文 article scientific artykuł naukowy სამეცნიერო სტატია 2008년 논문 scientific article articol științific επιστημονικό άρθρο bài báo khoa học artikulong pang-agham 2008年論文 บทความทางวิทยาศาสตร์ vedecký článok mokslinis straipsnis teaduslik artikkel vědecký článek 2008年论文 سائنسی مضمون tudományos cikk wetenschappelijk artikel ২০০৮-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ 2008年论文 artigo científico (publicado na 2008) מאמר מדעי 2008年论文 artigo científico 2008 թվականի հունիսին հրատարակված գիտական հոդված vitenskapelig artikkel научни чланак artículo científico publicado en 2008 научна статия 2008 nî lūn-bûn 2008 թուականի Յունիսին հրատարակուած գիտական յօդուած мақолаи илмӣ scienca artikolo bilimsel makale научни чланак vitskapeleg artikkel 2008年論文 artículu científicu espublizáu en 2008 2008年の論文 wissenschaftlicher Artikel vetenskaplig artikel مقالهٔ علمی artikull shkencor 2008年论文
p:P577
wds:Q33380148-7794EE42-997D-424A-8F34-F80E3493D95B
wdt:P577
2008-06-30T00:00:00Z
p:P407
wds:Q33380148-66D42EA2-98F1-48C8-9048-EDBCD8703F69
wdt:P407
wd:Q1860
p:P2860
wds:Q33380148-4C381061-82B8-463E-81C9-2D88F10FBE31 wds:Q33380148-5FF65504-DBE4-45FD-AB80-7A367970D7CD wds:Q33380148-68356479-0045-4130-BC14-E9FF94E6326C wds:Q33380148-0693F657-2549-496C-9B0E-5C3A79C696F6 wds:Q33380148-09B7E5B2-EC01-4EE8-A461-5CB904F82F01 wds:Q33380148-2E118CE0-CEC8-45AA-B145-F522CCCF549D wds:Q33380148-3150346B-88B0-44A1-879E-D408D732790C wds:Q33380148-338B47E6-DA8E-4A53-A9AF-63E4F53CEFFF wds:Q33380148-C31B101E-4C5C-4905-A660-72AC260466BE wds:Q33380148-E6B4CD73-496A-4DF2-9A1D-F77B89D49CA7 wds:Q33380148-F1EA7DBF-5352-4084-9007-51D67FB1EA5A wds:Q33380148-F2327802-9E98-49C3-8E04-4659316B2EA2 wds:Q33380148-F715282E-8C52-459B-B7BF-7E9AA13F8F11 wds:Q33380148-F75A2097-68F1-4804-BD35-5BC958B78E90 wds:Q33380148-FB8D9CBC-3950-4349-8238-561A0813A7FE wds:Q33380148-FF4DD7EF-9E3E-4ADA-BD87-8C3F4F97821B wds:Q33380148-8126BE2F-188E-4DA0-BC0F-B2E4D341AAD9 wds:Q33380148-8156F858-2F49-4BA7-A1CD-2EE1E521DD38 wds:Q33380148-8348F9D5-2E17-4644-98FE-C7EBC62C2C10 wds:Q33380148-850A37AC-18BE-42FE-B059-6DC27721F18D wds:Q33380148-863855C0-1C84-4E33-8A8F-7DB7DA2F6141 wds:Q33380148-97127208-DC57-4237-A7BD-AB237D3F3556 wds:Q33380148-97365DD6-9B1E-49C6-8902-6C14A052F0BF wds:Q33380148-9DC360F7-C76A-421D-9B0A-09C8199BD556 wds:Q33380148-A164A797-1A91-4C2B-A68C-5E31E4F36400 wds:Q33380148-B1EA44FC-E775-4017-A12B-3FEDB40C1EB7 wds:Q33380148-362C9D8D-B264-4C39-9405-3ABCC77A8560 wds:Q33380148-40215DCF-D81C-45E5-8304-FA029EF9D2F4 wds:Q33380148-49CA6665-9844-4902-916C-3D2BCC3B503C wds:Q33380148-4BC84A53-85D7-405A-962C-11817680CC09
wdt:P2860
wd:Q57106767 wd:Q44083625 wd:Q37919763 wd:Q54392122 wd:Q35823805 wd:Q36407162 wd:Q43554740 wd:Q54360479 wd:Q36343629 wd:Q68805065 wd:Q41005627 wd:Q43718516 wd:Q36351101 wd:Q34743618 wd:Q73516747 wd:Q40739600 wd:Q77848228 wd:Q35849784 wd:Q33344274 wd:Q69939192 wd:Q54110984 wd:Q34542232 wd:Q40668598 wd:Q34722375 wd:Q28247684 wd:Q71942113 wd:Q41337945 wd:Q80166478 wd:Q28303488 wd:Q33502338
p:P2093
wds:Q33380148-A87F5B36-8B8D-4597-95FD-40F446E05400 wds:Q33380148-997F7760-23C9-4D2B-9970-1C11C658631B wds:Q33380148-FB6D9A87-2CDD-4CFB-A7F5-A9EC1723F846 wds:Q33380148-38F55D88-26BD-4057-B1A6-80FDDA86B1B0 wds:Q33380148-5AF3BBB5-A2AC-4E43-84AB-01D61BE8D91F
wdt:P2093
Sandra M Bothun Joseph O Moore Stephen L George Richard M Stone Maria R Baer
rdfs:label
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.
skos:prefLabel
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.
schema:name
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.
p:P50
wds:Q33380148-1C37DB4A-EA1C-47E9-81C9-7ADFE3216D90 wds:Q33380148-5140BC57-D291-4EF8-B2F8-DDFA0763B02B wds:Q33380148-578FC625-CC27-4F5A-A8C9-089130A62109 wds:Q33380148-4BB481DD-379E-49BE-AF16-B7F717A0A624 wds:Q33380148-BC4FCB39-F92A-4AEE-9FB7-63785F606800 wds:Q33380148-9A1BE7A7-0E63-4A21-8B6C-93CF641002CA wds:Q33380148-7F219F15-C233-4CF3-9B1D-F5C940F8AC62 wds:Q33380148-DB7B5132-C53B-4BE5-8616-7E98463F6089
wdt:P50
wd:Q114529746 wd:Q90696849 wd:Q97333782 wd:Q66385542 wd:Q4793409 wd:Q41899936 wd:Q114413078 wd:Q90410343
p:P1476
wds:Q33380148-F932AB69-3821-4242-B720-1471886F9133
wdt:P1476
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.
p:P304
wds:Q33380148-142A6CDC-3533-41AC-B4DF-FC3DF9D0AA17
wdt:P304
4934-4939
p:P31
wds:Q33380148-309BED0F-A805-4D23-8283-AD746B3A5FE9
wdt:P31
wd:Q13442814
p:P921
wds:Q33380148-BC6D2ABC-EB4C-4A5F-97C5-12ED00273826 wds:Q33380148-5985dfa5-de03-4f0b-b300-6d7a4aa61b49 wds:Q33380148-0B7E2418-F3DC-42BA-811F-AD36124BD9E5 wds:Q33380148-17FDFDBF-2392-4769-BDF5-0FCFF8609785
wdt:P921
wd:Q1427096 wd:Q29496 wd:Q194908 wd:Q264118
p:P698
wds:Q33380148-FD166C3E-1F89-48C8-BEE4-3C172D75F18A
wdtn:P698
n12:18591543
wdt:P698
18591543
p:P1433
wds:Q33380148-D1188CC9-D53A-4CEA-AD1B-25ED075B0439
wdt:P1433
wd:Q400292
p:P433
wds:Q33380148-7DE43BE6-90B4-4D0C-BF3F-523130342943
p:P478
wds:Q33380148-03F13734-DDB3-4C1B-AFC5-70FE1E953441
wdt:P433
30
wdt:P478
26
p:P356
wds:Q33380148-49ADE5A1-7A89-403A-9192-0259C80FA8F9
wdtn:P356
n10:JCO.2008.17.0472
wdt:P356
10.1200/JCO.2008.17.0472
p:P932
wds:Q33380148-ECE5F300-E04C-4665-930F-04064D308775
wdt:P932
2652081